Radioimmunotherapy: A New Treatment Modality for B-Cell Non-Hodgkin’s Lymphoma
Radioimmunotherapy: A New Treatment Modality for B-Cell Non-Hodgkin’s Lymphoma
We applaud Ghobrial and
Witzig for their comprehensive
and balanced article on
"Radioimmunotherapy: A New Treatment
Modality for B-cell Non-
Hodgkin's Lymphoma." These
authors have provided a review that
will serve the oncologist and oncology
patient well. They have not engaged
in arcane and tedious discussion
of which anti-CD20 monoclonal antibody
(ibritumomab tiuxetan [Zevalin]
[I-131] tositumomab [Bexxar]), or radionuclide
(yttrium-90 [Y-90] or
I-131), or dosing method is better.
Wisely, Ghobrial and Witzig have provided
accurate distillates of the many
publications on these exciting drugs.
Because no rigorous body of data
clearly indicates that one drug is better
than the other, these debates only
confuse the oncologist and are better
left to the "technocrat."
New Treatment Paradigm
What is important to the oncologist and patient with non-Hodgkin's lymphoma (NHL) is that a paradigm change has occurred. After decades of adding chemotherapy drugs and regimens without altering therapeutic outcomes,[ 1] the management of NHL has been dramatically influenced by monoclonal antibodies. Whether used for immunotherapy or radioimmunotherapy, three anti-CD20 monoclonal antibodies have recently been approved because of their remarkable therapeutic effects in patients with chemotherapy- resistant, low-grade NHL.[2-4] Radioimmunotherapy is a method by which systemic radiotherapy is delivered to malignant cells using monoclonal antibodies, which target NHL antigens, as carriers of therapeutic radionuclides like Y-90 or I-131. Reflecting the impact of the radiation from the radionuclide, overall response rates and complete remission rates were two to four times greater for Y-90-labeled ibritumomab tiuxetan, compared to rituximab (Rituxan), the anti-CD20 monoclonal antibody alone, in the randomized, pivotal trial. Similar therapeutic outcome enhancements were reported for tositumomab/I-131-labeled tositumomab, as compared to the most recent chemotherapy regimen that the patient had received. Whereas rituximab immunotherapy for NHL quickly came into widespread use after its approval, it should be noted that radioimmunotherapy using tositumomab/ I-131 tositumomab or ibritumomab tiuxetan has thus far been slow to be incorporated into the management of NHL. Toxicity and Logistics
It is appropriate to ask the question, "Why the difference?" Clearly the efficacy profile of ibritumomab tiuxetan has been shown to be superior to that of rituximab,[ 3] and that of tositumomab/ I-131 tositumomab to the most recent chemotherapy regimen. While much is made of the toxicity associated with radioimmunotherapy, it has proven highly attractive to patients in contrast to chemotherapy. Furthermore, there is no substantive toxicity argument.[5,6] It is an advantage that the hematologic toxicity develops slowly and predictably after radioimmunotherapy. Neutropenic sepsis and bleeding are rare, in contrast to the frequency of such events seen with chemotherapy.[3,4] Subsequent treatment has been shown to be practicable and uncomplicated despite somewhat protracted duration of the hematologic toxicity after radioimmunotherapy.[7,8] Logistic considerations are sometimes offered as an impediment to radioimmunotherapy. Although the drugs must be specially ordered, they are readily available. It is true that a second specialist, the nuclear medicine physician, must be involved in the same way that the radiation oncologist must be involved when the NHL patient requires local radiotherapy. Nevertheless, ibritumomab tiuxetan and tositumomab/I-131 tositumomab have been shown to present minimal radiation safety issues for health-care personnel and society, and these considerations are readily managed. Superior Results to Standard Therapy
All things considered, we must acknowledge that the management of low-grade NHL has been remarkably improved in recent years because of the availability of new drugs, including monoclonal antibody-based drugs.[10-14] As a single agent, rituximab is less effective in aggressive NHL. Ibritumomab tiuxetan and tositumomab/ I-131 tositumomab are effective in transformed and aggressive NHL[4,5,15]; another I-131-labeled antilymphoma monoclonal antibody (Lym-1) was particularly effective in treating diffuse large-cell NHL. The therapeutic efficacy/safety profiles of radioimmunotherapy are highly attractive to the informed patient and physician, so there is no basis for deferring the use of ibritumomab tiuxetan and tositumomab/I-131 tositumomab. To the contrary, evidence of high response rates associated with du- rable remissions and excellent quality of life suggest that the treatment algorithm for the management of patients with NHL should include these drugs at an early stage. As a single agent given in a single dose to previously untreated patients with advanced follicular lymphoma, tositumomab/I-131 tositumomab provided an overall response rate of 95% and a complete remission rate of 74%, despite the fact that 63% of the patients had bone marrow involvement. The 5-year progression- free survival for these patients was 62%. Toxicity was minimal, and none of the patients have developed myelodysplastic syndrome to date. And the best is yet to come. The cure of "incurable" NHL is a reasonable expectation with better versions of radioimmunotherapeutic drugs and strategies. Administration of a second dose of radiolabeled monoclonal antibody has been shown to convert partial remissions to complete remissions.[ 16] As might be expected from the experience with chemotherapy and radiotherapy, administration of multiple doses of radiolabeled monoclonal antibodies- referred to as a fractionation strategy-has been shown to be advantageous in preclinical models and in clinical trials. Radiometal chelators, shown to be superior to those currently used, are available to improve conventional radioimmunotherapy.[ 19,20] Importantly, pretargeting radioimmunotherapy strategies have been shown to provide better therapeutic indices than standard one-step radioimmunotherapy.[21,22] These strategies pretarget a bifunctional monoclonal antibody to the malignant NHL cells followed by the administration of a small radionuclide carrier that quickly penetrates and is concentrated in the malignant cells, or excreted in the urine. Conclusions
In summary, radioimmunotherapy should be incorporated into the fundamental management of patients with B-cell NHL soon after these patients have proven to be incurable. Although remarkable progress has been made since the use of radioimmunotherapy for B-cell malignancies was first reported,[ 23] readily predictable improvements using better drugs, strategies, and combinations with other drugs are certain to make these approaches integral to the management of patients with NHL.
2. Maloney DG, Grillo-Lopez AJ, White CA, et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188-2195, 1997.
3. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90- labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20:2453-2463, 2002.
4. Kaminiski MS, Zelenetz AD, Press OW, et al: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 19:3918-3928, 2001.
5. Witzig TE, White CA, Gordon LI: Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin’s lymphoma. J Clin Oncol 21:1263-1270, 2003.
6. Schenkein D, Leonard J, Harwood S: Interim Safety results of Bexxar in a large multicenter expanded access study (abstract 1138). Proc Am Soc Clin Oncol 20:285a, 2001.
7. Ansell SM, Ristow KM, Habermann TM: Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with Yttrium- 90 ibritumomab tiuxetan for non- Hodgkin’s lymphoma. J Clin Oncol 20:3885- 3890, 2002.
8. Wahl RL, Tidmarsh G, Kroll S, et al: Successful re-treatment of non-Hodgkin’s lymphoma (NHL) with iodine-131 anti-B1 antibody (abstract 156). Proc Am Soc Clin Oncol 17:40a, 1998.
9. Siegel JA: Revised nuclear regulatory commission regulations for release of patients administered radioactive materials: Outpatient iodine-131 anti-B1 therapy. J Nucl Med 39:28S- 33S, 1998.
10. Dillman RO: Radiolabeled anti-CD20 monoclonal antibodies for the treatment of Bcell lymphoma. J Clin Oncol 20:3545-3557, 2002.
11. Cheson B: Radioimmunotherapy of non- Hodgkin’s lymphomas. Blood 101:391-398, 2003.
12. DeNardo GL, O’Donnell RT, Oldham RK, et al: A revolution in the treatment of non- Hodgkin’s lymphoma. Cancer Biother Radiopharm 13:213-223, 1998.
13. Juweid ME: Radioimmunotherapy of Bcell non-Hodgkin’s lymphoma: From clinical trials to clinical practice. J Nucl Med 43:1507- 1529, 2002.
14. Juweid M, DeNardo GL, Graham M, et al: Radioimmunotherapy: A novel treatment modality for B-Cell non-Hodgkin’s lymphoma. Cancer Biother Radiopharm 18:673-674, 2003.
15. Witzig TE, White CA, Wiseman GA, et al: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin’s lymphoma. J Clin Oncol 17:3793-3803, 1999.
16. DeNardo GL, DeNardo SJ, Goldstein DS, et al: Maximum tolerated dose, toxicity, and efficacy of I-131 Lym-1 antibody for fractionated radioimmunotherapy of non- Hodgkin’s lymphoma. J Clin Oncol 16:3246- 3256, 1998.
17. Kaminski M, Tuck M, Regan D: High response rates and durable remissions in patients with previously untreated, advancedstage, follicular lymphoma treated with tositumomab and iodine I-131 tositumomab (Bexxar). Blood 100:356a, 2002.
18. DeNardo GL, Schlom J, Buchsbaum DJ, et al: Rationales, evidence and design considerations in multiple dose (fractionated) radioimmunotherapy. Cancer 94:1332-1348, 2002.
19. DeNardo GL, Kroger LA, DeNardo SJ, et al: Comparative toxicity studies of yttrium- 90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer 73:1012-1022, 1994.
20. Griffiths GL, Govindan SV, Sharkey RM, et al: 90Y-DOTA-hLL2: An agent for radioimmunotherapy of non-Hodgkin’s lymphoma. J Nucl Med 44:77-84, 2003.
21. Weiden PL, Breitz HB: Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin’s lymphoma (NHL). Crit Rev Oncol Hematol 40:37-51, 2001.
22. Press OW, Corcoran M, Subbiah K, et al: A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20- expressing lymphoma xenografts. Blood 98:2535-2543, 2001.
23. DeNardo SJ, DeNardo GL, O’Grady LF, et al: Treatment of B cell malignancies with I- 131 Lym-1 monoclonal antibodies. Int J Cancer 3(suppl):96-101, 1988.